CA2826548A1 - Crystallization method and bioavailability - Google Patents

Crystallization method and bioavailability Download PDF

Info

Publication number
CA2826548A1
CA2826548A1 CA2826548A CA2826548A CA2826548A1 CA 2826548 A1 CA2826548 A1 CA 2826548A1 CA 2826548 A CA2826548 A CA 2826548A CA 2826548 A CA2826548 A CA 2826548A CA 2826548 A1 CA2826548 A1 CA 2826548A1
Authority
CA
Canada
Prior art keywords
composition
api
coformer
anyone
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2826548A
Other languages
English (en)
French (fr)
Inventor
Mazen Hanna
Ning SHAN
Miranda L. Cheney
David R. Weyna
Raymond Houck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grünenthal GmbH
Original Assignee
Thar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/043892 external-priority patent/WO2011014766A2/en
Priority claimed from PCT/US2010/043916 external-priority patent/WO2011014781A1/en
Application filed by Thar Pharmaceuticals Inc filed Critical Thar Pharmaceuticals Inc
Publication of CA2826548A1 publication Critical patent/CA2826548A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2826548A 2010-02-06 2011-02-02 Crystallization method and bioavailability Abandoned CA2826548A1 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US30211010P 2010-02-06 2010-02-06
US61/302,110 2010-02-06
US31287910P 2010-03-11 2010-03-11
US61/312,879 2010-03-11
US31850310P 2010-03-29 2010-03-29
US61/318,503 2010-03-29
US33302810P 2010-05-10 2010-05-10
US33304110P 2010-05-10 2010-05-10
US61/333,028 2010-05-10
US61/333,041 2010-05-10
US35954410P 2010-06-29 2010-06-29
US61/359,544 2010-06-29
USPCT/US10/43892 2010-07-30
USPCT/US10/43916 2010-07-30
PCT/US2010/043892 WO2011014766A2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
US12/847,568 US8399023B2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
PCT/US2010/043916 WO2011014781A1 (en) 2009-07-31 2010-07-30 Novel oral forms of a phosphonic acid derivative
US12/847,568 2010-07-30
US37981410P 2010-09-03 2010-09-03
US61/379,814 2010-09-03
US45577810P 2010-10-26 2010-10-26
US61/455,778 2010-10-26
PCT/US2011/023427 WO2011097269A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Publications (1)

Publication Number Publication Date
CA2826548A1 true CA2826548A1 (en) 2011-08-11

Family

ID=44355747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2826548A Abandoned CA2826548A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Country Status (15)

Country Link
EP (1) EP2531200B1 (enExample)
JP (2) JP5792748B2 (enExample)
AU (2) AU2012216632B2 (enExample)
CA (1) CA2826548A1 (enExample)
CY (1) CY1119192T1 (enExample)
DK (1) DK2531200T3 (enExample)
ES (1) ES2638072T3 (enExample)
HR (1) HRP20171201T1 (enExample)
HU (1) HUE035744T2 (enExample)
IL (1) IL221306A0 (enExample)
LT (1) LT2531200T (enExample)
PL (1) PL2531200T3 (enExample)
PT (1) PT2531200T (enExample)
SI (1) SI2531200T1 (enExample)
WO (1) WO2011097269A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102268023B (zh) * 2011-08-15 2013-04-17 南京丰融化学技术有限公司 头孢类衍生物cxd的晶型
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
PL2849758T3 (pl) * 2012-05-14 2018-08-31 Antecip Bioventures Ii Llc Kompozycje zawierające kwas zoledronowy lub pokrewne związki do uśmierzania bólu zapalnego i stanów powiązanych
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
US11406713B2 (en) 2013-03-15 2022-08-09 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations
KR101739244B1 (ko) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
MX2018002627A (es) * 2015-09-18 2018-12-17 Gruenenthal Chemie Metodo de cristalizacion y biodisponibilidad.
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR102723076B1 (ko) * 2016-12-15 2024-11-28 제이투에이치바이오텍 (주) 3성분 코크리스탈
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
EP1416919A1 (en) 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
ES2322592T3 (es) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102070668B (zh) * 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法

Also Published As

Publication number Publication date
WO2011097269A1 (en) 2011-08-11
JP6190429B2 (ja) 2017-08-30
HUE035744T2 (en) 2018-05-28
IL221306A0 (en) 2012-10-31
AU2016219653A1 (en) 2016-09-15
WO2011097269A9 (en) 2012-12-27
JP2016006096A (ja) 2016-01-14
AU2016219653B2 (en) 2018-05-31
DK2531200T3 (en) 2017-09-11
ES2638072T3 (es) 2017-10-18
CY1119192T1 (el) 2018-02-14
AU2012216632B2 (en) 2016-05-26
JP5792748B2 (ja) 2015-10-14
JP2013519632A (ja) 2013-05-30
PT2531200T (pt) 2017-08-24
SI2531200T1 (sl) 2017-12-29
EP2531200A4 (en) 2014-01-08
HRP20171201T1 (hr) 2017-10-06
EP2531200B1 (en) 2017-07-12
PL2531200T3 (pl) 2017-10-31
LT2531200T (lt) 2017-09-25
EP2531200A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
AU2012216632B2 (en) Crystallization Method and Bioavailability
US9169279B2 (en) Crystallization method and bioavailability
US10323052B2 (en) Crystallization method and bioavailability
US20190083407A1 (en) Crystallization method and bioavailability
US10093691B2 (en) Crystallization method and bioavailability
US10195218B2 (en) Crystallization method and bioavailability

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160129

FZDE Discontinued

Effective date: 20190307